Cancer immunotherapy: a future paradigm shift in the treatment of non-small cell lung cancer
about
Long Non-coding RNAs and Their Roles in Non-small-cell Lung CancerCheckpoint Inhibitors and Their Application in Breast CancerRegulation of Natural Killer Cell Function by STAT3Cancer stem cells and immunoresistance: clinical implications and solutionsPredictive factors for immunotherapy in melanomaAdvances in immunotherapy for treatment of lung cancerAdvances in the diagnosis, treatment and prognosis of malignant pleural mesotheliomaThe anticancer immune response of anti-PD-1/PD-L1 and the genetic determinants of response to anti-PD-1/PD-L1 antibodies in cancer patientsSpotlight on pembrolizumab in non-small cell lung cancer: the evidence to dateImmune checkpoint blockade opens an avenue of cancer immunotherapy with a potent clinical efficacyRisk of hepatotoxicity in cancer patients treated with immune checkpoint inhibitors: A systematic review and meta-analysis of published data.Has aidi injection the attenuation and synergistic efficacy to gemcitabine and cisplatin in non-small cell lung cancer? A meta-analysis of 36 randomized controlled trials.Clinical outcomes using carbon-ion radiotherapy and dose-volume histogram comparison between carbon-ion radiotherapy and photon therapy for T2b-4N0M0 non-small cell lung cancer-A pilot studyPrognostic impact of EGFR mutation in non-small-cell lung cancer patients with family history of lung cancer.Association of MAGE A1-6 Expression with Lung Cancer Progression.Lung cancer in the era of precision medicineCD45RO(+) Memory T Lymphocytes--a Candidate Marker for TNM-Immunoscore in Squamous Non-Small Cell Lung Cancer.Anti-CCR4 monoclonal antibody enhances antitumor immunity by modulating tumor-infiltrating Tregs in an ovarian cancer xenograft humanized mouse modelCan Aidi injection alleviate the toxicity and improve the clinical efficacy of radiotherapy in lung cancer?: A meta-analysis of 16 randomized controlled trials following the PRISMA guidelines.Profiling cancer testis antigens in non-small-cell lung cancer.Intra-tumoral heterogeneity in the expression of programmed-death (PD) ligands in isogeneic primary and metastatic lung cancer: Implications for immunotherapy.Prognostic significance of programmed death-1 and programmed death-ligand 1 expression in patients with esophageal squamous cell carcinoma.SEP enhanced the antitumor activity of 5-fluorouracil by up-regulating NKG2D/MICA and reversed immune suppression via inhibiting ROS and caspase-3 in mice.Can Aidi injection restore cellular immunity and improve clinical efficacy in non-small-cell lung cancer patients treated with platinum-based chemotherapy? A meta-analysis of 17 randomized controlled trials following the PRISMA guidelines.Necitumumab for non-small cell lung cancer.Clinical Applications of Immunotherapy Combination Methods and New Opportunities for the Future.Strategies for clinical implementation of TNM-Immunoscore in resected nonsmall-cell lung cancer.Pembrolizumab in the treatment of metastatic non-small cell lung cancer: a review of current evidence.Talimogene laherparepvec in the treatment of melanoma.Phase I Trial of Intratumoral Injection of CCL21 Gene-Modified Dendritic Cells in Lung Cancer Elicits Tumor-Specific Immune Responses and CD8+ T-cell Infiltration.Increased HAGLR expression promotes non-small cell lung cancer proliferation and invasion via enhanced de novo lipogenesis.Immune checkpoint therapy for non-small-cell lung cancer: an update.PROTOCADHERIN 7 Acts through SET and PP2A to Potentiate MAPK Signaling by EGFR and KRAS during Lung Tumorigenesis.Assessment of the PD-L1 status by immunohistochemistry: challenges and perspectives for therapeutic strategies in lung cancer patients.Immune checkpoint blockade as a potential therapeutic target in non-small cell lung cancer.Diagnosis and Molecular Classification of Lung Cancer.Resistance to anticancer immunity in cancer patients: potential strategies to reverse resistance.Genomic Analysis of Immune Cell Infiltrates Across 11 Tumor Types.A combination of anti-PD-L1 mAb plus Lm-LLO-E6 vaccine efficiently suppresses tumor growth and metastasis in HPV-infected cancers.Image Analysis-based Assessment of PD-L1 and Tumor-Associated Immune Cells Density Supports Distinct Intratumoral Microenvironment Groups in Non-small Cell Lung Carcinoma Patients
P2860
Q26743412-30E879D5-1A7B-4B8F-A843-B48B87D96E58Q26745442-6D9E94AF-1874-4C55-9833-1357EA574D2CQ26752551-BFFB296B-7812-4DF0-8D15-4E8D4A1AFCB7Q26769757-B5106A8D-50AD-4948-B8C3-9F58AEC512FFQ26778765-AF344868-8FC5-4574-AEB9-3EB5A337B1CFQ26778790-5A501306-CA51-478F-BEC1-11B82BB0DE9CQ26787294-47AF2DFA-9F52-46C5-981B-0DB4C0E0E733Q26797478-0B88762F-3553-4354-B6C0-BAF1E31E9BAFQ28067610-4BC3260B-F5DE-4985-970A-83E57A3521E0Q28082914-6F7AA595-4B52-40D8-8ED8-61D848CA61A3Q31171172-349A3369-27A6-47F4-A977-770F596C3B70Q33437216-99728F9B-4D75-419A-8911-E0B98091592EQ33554464-2C0B9211-AEFC-49A0-96B7-00D5CED38650Q33653097-4C6E3180-3787-42C9-A94F-45C9FDDDA915Q33820811-BAB9AD88-6F09-4A28-94B4-F044A2D3B808Q35861107-0C1C0E3E-309B-4E4E-B9A8-6C14B1BF7A00Q36378871-6541007A-A696-4D0D-A3D5-608F7F810449Q36821149-88ADDB33-1AFA-4027-AFFE-74AE0B3A0CD9Q37226187-59977530-D823-413A-A096-F8A5B2481299Q37277266-9DF7CBF2-9DB6-43C1-B2CA-1CC843D57724Q37308194-73FF4440-6F31-4726-8355-D46039072578Q37327597-FAC32F2B-64BD-4519-AB44-2948C1EEDFF2Q37580265-D04E4C06-AFBE-40A3-A2FD-126BC227D2FDQ38375732-691B37CC-8E40-4CBC-8EC6-5645AB29D679Q38519582-A576D4AB-3DF3-4E21-9135-B3859523DEA7Q38636430-24468F35-C3BE-4DF4-A3A4-EE7E6FCE8BC1Q38636708-68982286-6B7E-49A7-9E90-93E328D764DDQ38640845-64E46734-FC5A-4704-ABA1-06125EA3A79AQ38656524-F66422E2-C00A-42E7-AF15-7EE97D4EF309Q38688006-E9079066-FD8C-496D-B062-19544DC3F594Q38706056-11A2258B-438A-497C-A1E1-69F37658A63EQ38727542-9D54C342-9440-4EA3-B3BC-768DC3C0B7BBQ38732488-12750D47-902D-4984-B29E-6611123CBFC6Q38749966-AF904CE7-E1BE-4429-9C3A-90153F11F96CQ38899873-618574D0-0991-4594-8A6C-CBD5F4E208FAQ38930336-F701B3E3-105B-4550-9317-64ACC7ED4D77Q39013616-42D82321-5F95-4A2C-A0CF-669B9579E42DQ39661584-FF10D624-2087-45E8-AF77-0063C0A7B5E8Q40099137-E5CFFFD0-7999-4E60-91C0-88BC40E779A6Q41424696-F252D28A-63A1-4562-8E2A-4FFF8218B7AD
P2860
Cancer immunotherapy: a future paradigm shift in the treatment of non-small cell lung cancer
description
2015 nî lūn-bûn
@nan
2015 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2015 թվականի մարտին հրատարակված գիտական հոդված
@hy
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
name
Cancer immunotherapy: a future ...... of non-small cell lung cancer
@ast
Cancer immunotherapy: a future ...... of non-small cell lung cancer
@en
Cancer immunotherapy: a future ...... of non-small cell lung cancer
@nl
type
label
Cancer immunotherapy: a future ...... of non-small cell lung cancer
@ast
Cancer immunotherapy: a future ...... of non-small cell lung cancer
@en
Cancer immunotherapy: a future ...... of non-small cell lung cancer
@nl
prefLabel
Cancer immunotherapy: a future ...... of non-small cell lung cancer
@ast
Cancer immunotherapy: a future ...... of non-small cell lung cancer
@en
Cancer immunotherapy: a future ...... of non-small cell lung cancer
@nl
P3181
P1476
Cancer immunotherapy: a future ...... of non-small cell lung cancer
@en
P2093
J. R. Brahmer
V. K. Anagnostou
P304
P3181
P356
10.1158/1078-0432.CCR-14-1187
P407
P577
2015-03-01T00:00:00Z